Oral Solid Dose Scale-Up Readiness Checklist
Contents
- Purpose and scope
- How to use the checklist
- Scale-up readiness worksheet
- Study and evidence checklist
- Worked fictional example
- Common mistakes
- Frequently asked questions
- Does ICH Q8(R2) set a required scale-up ratio?
- Does this checklist replace process validation?
- When does FDA SUPAC-IR apply?
- How long should batch-specific records be retained?
- References
- Related reading
In short: Scale-up readiness is a documented review of whether product and process knowledge support a proposed change in manufacturing scale or equipment. This checklist helps a development or manufacturing team connect process differences with quality risks, controls, evidence and required decisions. It does not set a batch-size multiplier or replace the applicable change-control, validation or regulatory assessment.
Purpose and scope
Moving an oral solid dosage process to a different batch size can change material movement, mixing, heat and mass transfer, granulation, drying, lubrication, compression or coating behaviour. The scale change may involve a different machine, a different operating principle, a new site or several changes at once. The relevant risks depend on the formulation and process, so one scale-up checklist cannot establish universal acceptance criteria.
ICH Q8(R2) describes pharmaceutical development as a way to build scientific understanding of a product and its manufacturing process. Section 2.3 says the process development programme should identify critical process parameters to be monitored or controlled, and that process development studies should provide the basis for process improvement, validation and process control. ICH Q9(R1) describes risk assessment, risk control, communication and review as parts of quality risk management; the effort, formality and documentation should be commensurate with the level of risk, and the rigour and formality should reflect the uncertainty, importance and complexity of the issue.
FDA’s November 1995 SUPAC-IR guidance is specifically about certain post-approval changes to immediate-release solid oral dosage forms in US applications. It is not a universal scale-up rule for all products, markets or development batches. Assess the requirements and commitments that apply to the product’s actual markets. For process-specific details, see the granulation endpoint study, critical quality attributes at tablet compression and process validation guide.
How to use the checklist
- Describe the proposed change. State the current and proposed batch sizes, sites, equipment, process steps, materials, controls and intended implementation date. Separate simultaneous changes so the team can see which differences may affect quality.
- Define the quality question. Identify the product quality attributes and process performance outcomes that could be affected. Use the product’s development history, prior batches, deviations, complaints and risk assessments.
- Compare current and proposed operations. Assess equipment design and operating principle, geometry, capacity, sensor location, material transfer, process sequence, automation and operator interventions. Record relevant differences rather than relying only on nominal capacity.
- Connect factors to outcomes. Map material attributes and process parameters to the quality attributes. Identify what is known, what is uncertain and what evidence is needed to resolve important uncertainty.
- Plan studies and controls. Define the study question, protocol, sampling, methods, data analysis, acceptance criteria and response to unexpected results before the work starts. Proposed ranges and local readiness gates must have a scientific basis.
- Assess lifecycle requirements. Use the applicable change-control procedure to decide whether qualification, process validation, continued verification, stability work, filing or regulatory notification is required. A completed checklist does not itself authorise a change.
- Document the decision. Record reviewers, evidence, limitations, actions, responsibilities, target dates and closure criteria. Revisit the assessment when new information or changes could alter the original risk decision.
Scale-up readiness worksheet
Complete each relevant row and explain why a topic is not applicable. Reference controlled documents by identifier and version, and attach the supporting data where appropriate. Add rows for product-specific risks.
| Readiness topic | Questions for the team | Evidence reference | Risk / gap and rationale | Action, owner and due date | Closure evidence |
|---|---|---|---|---|---|
| Change scope | What is changing, and what remains the same? | ||||
| Product and process knowledge | Which attributes and process outcomes may be affected? | ||||
| Materials | Are material sources, lots, grades or relevant properties different? | ||||
| Equipment | What differs in geometry, operating principle, capacity or controls? | ||||
| Process parameters | Which parameters are critical or need monitoring at the proposed scale? | ||||
| Measurement systems | Are sensors, methods and sampling representative and fit for use? | ||||
| Downstream operations | Could granule, blend or tablet properties affect later steps? | ||||
| Study protocol | Are runs, controls, methods and data analysis planned in advance? | ||||
| Validation and verification | What qualification, validation or continued verification applies? | ||||
| Regulatory assessment | Which markets, applications and commitments govern the change? | ||||
| Documentation and training | Are approved procedures, records and training ready for implementation? | ||||
| Final decision | Who reviews the evidence and authorises the next step? |
Study and evidence checklist
Before a scale-up activity begins, confirm that the protocol identifies the objective, responsible functions, products and batches, equipment, materials, parameters, methods, sample plan, data handling and decision criteria. Where a study uses a risk-ranking method or a local readiness gate, define that method in the site quality system. Any company-selected threshold or target is an example in-house criterion when used here for teaching; it is not a regulatory value.
During execution, record actual settings and observations, not only target values. Link each sample to its run, process stage, location and analytical result. Document deviations and unexpected outcomes using the applicable procedure. After execution, compare the results with the predefined criteria, assess whether the study was informative, and state what the evidence can and cannot support.
Review downstream results as well as intermediate process data. A process parameter may appear stable while a downstream quality attribute changes. Conversely, a difference in an equipment setting does not automatically mean the product is at risk; assess it against relevant evidence and the product’s control strategy.
Worked fictional example
Fictional example — every batch size and local gate below is an example in-house criterion, not a regulatory limit. A team plans to move a direct-compression tablet process from a 10 kg development batch to a 40 kg engineering batch and use a blender with a different vessel geometry. The team compares blend uniformity risk, fill behaviour, mixing profile, discharge, transfer and compression performance. It identifies powder segregation during discharge as an uncertainty and plans a protocol with defined sampling locations and product-specific analytical methods. The team also reviews compression outcomes against its approved development criteria and evaluates whether the proposed process can be controlled at the intended scale.
The readiness decision is not based on the 4:1 scale ratio. The team documents the equipment differences, data, limitations and follow-up study needed before recommending routine implementation. Any post-approval filing or notification decision is assessed separately for the markets concerned.
Common mistakes
- Using batch-size ratio as the main argument. A ratio alone does not show that process performance or product quality will remain controlled.
- Assuming a larger machine is equivalent because it has the same name. Compare operating principles, geometry, controls, sensor location and material handling.
- Selecting limits after seeing the results. Define the study question and decision criteria in advance. Explain any additional analysis that was not planned.
- Ignoring material variation. Material attributes can affect the same process differently at a new scale. Include relevant raw material information in the study rationale.
- Using SUPAC-IR as a global classification table. The FDA guidance is limited to its stated US post-approval scope for immediate-release solid oral dosage forms. Determine the applicable requirements for each market and product.
- Treating readiness as the approval step. The checklist records evidence and gaps; approved change control and any required quality or regulatory decisions still govern implementation.
- Dropping unusual data without explanation. Preserve raw results and deviations, investigate scientifically and record the rationale for any exclusion or repeat.
Frequently asked questions
Does ICH Q8(R2) set a required scale-up ratio?
No. ICH Q8(R2) provides pharmaceutical development guidance and discusses process understanding, critical parameters, process controls and how scale or equipment can relate to process robustness. It does not set a universal batch-size ratio for oral solid dosage products.
Does this checklist replace process validation?
No. Use the checklist to identify readiness questions and evidence gaps. Qualification, process validation, continued process verification and change control should follow the applicable product and site requirements.
When does FDA SUPAC-IR apply?
FDA’s November 1995 SUPAC-IR guidance gives recommendations for specified post-approval changes involving immediate-release solid oral formulations submitted through the US NDA, ANDA or AADA pathways. Check the current application, FDA guidance and other applicable requirements before using it for a specific change.
How long should batch-specific records be retained?
Keep batch-specific production or control records at least 1 year after the expiry of the respective product batch; EU GMP Volume 4, Chapter 4 §4.11 also sets a longer period when 5 years after Qualified Person certification exceeds that period. 21 CFR 211.180(a) sets at least 1 year after expiry for applicable production, control or distribution records. Apply longer or product-specific periods where they govern.
References
- International Council for Harmonisation, ICH Q8(R2): Pharmaceutical Development, current Step 4 version dated August 2009, especially Part I §2.3 and Part II §2.4.4: official PDF.
- International Council for Harmonisation, ICH Q9(R1): Quality Risk Management, final version adopted 18 January 2023: official PDF.
- U.S. Food and Drug Administration, SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes, November 1995, final guidance: FDA guidance page and guidance PDF.
- European Commission, EudraLex Volume 4, Chapter 4: Documentation, revision 1, effective 30 June 2011, §§4.11–4.12: official PDF.
- 21 CFR Part 211, current eCFR, §211.180(a): eCFR.
Related reading
Related articles
Granulation Endpoint Study Protocol and Data Sheet
Plan a product-specific granulation endpoint study with an ICH Q8(R2) grounded protocol, data sheet, worked example and controls for interpreting results.
Tablet Coating Defects: Causes and Troubleshooting Guide
Understand common tablet coating defects, likely process causes and safe checks for troubleshooting without applying unverified settings or acceptance limits.
Pharma Jobs for Freshers in India: Roles and How to Apply
Pharma jobs for freshers in India: entry roles for D.Pharm, B.Pharm, M.Pharm, B.Sc and ITI candidates, where genuine openings are posted, walk-in tips and safety checks.
Pharma Production Interview Questions for Freshers with Answers
Pharma production interview questions for freshers with model answers on GMP, granulation, compression, coating, line clearance, BMR and yield in OSD plants.